



Garland Lecture 2026

F E A T U R I N G

Gunda I. Georg

Regents Professor, Robert Vince Endowed Chair and McKnight Chair
Director, Institute for Therapeutics Discovery and Development
University of Minnesota, Minneapolis, MN

*Editor-in-Chief, Journal of Medicinal Chemistry (2012–2020).
Co-inventor of one FDA-approved drug and three compounds
in clinical trials, including the first non-hormonal male
contraceptive to enter human trials in 60 years.*



LECTURE TITLE

Discovery and Development of YCT-529: Targeting the Retinoid Signalling Pathway for Effective and Reversible Oral Male Contraception

A B S T R A C T

To reduce the high rates of unintended pregnancies worldwide, more effective contraceptive options for both women and men are needed. While women have access to multiple contraceptive methods, options for men are limited to condoms and vasectomy. Introducing a new male birth control method would offer an alternative for family planning and help balance the responsibility between genders. Hormonal male contraceptives have been studied for many years, but none have yet reached the market. As a result, several laboratories are exploring non-hormonal contraceptive agents. This lecture covers the discovery and development of the first-in-class selective retinoic acid receptor alpha (RAR α) antagonist, including preclinical studies of YCT-529 in mice and non-human primates, as well as findings from ongoing clinical trials.

D A T E

April 23, 2026

Thursday

T I M E

3:30 PM

All are welcome

V E N U E

Peacock Auditorium

BESB 100, TAMUK